NCT03240393View on ClinicalTrials.gov

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2018

Primary Completion Date

October 26, 2021

Study Completion Date

October 26, 2021

Conditions
CarcinomaNon-Small-Cell Lung Cancer
Interventions
DRUG

INC280

cMET GCN ≥ 6 cMET GCN ≥ 4 and \< 6 cMET mutations

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY